arsenic trioxide / Generic mfg. - LARVOL DELTA

Curcumin combined with arsenic trioxide enhances autophagy and immune surveillance to inhibit immune escape in acute myeloid leukemia. (PubMed, Int Immunopharmacol) - "In the AML mouse model, the combination of CUR and ATO exerted a synergistic anti-tumor effect during the progression of AML. In the in vitro KG-1a cell model, it was demonstrated that CUR combined with ATO promoted apoptosis and inhibited proliferation in KG-1a cells through upregulation of the pro-apoptotic protein Caspase3 and downregulation of the anti-apoptotic protein Bcl-2, which was accompanied by a significant increase in autophagosomes in KG-1a cells. In both the co-culture and in vivo models, CUR combined with ATO enhanced the immunotoxic effects of NK cells on KG-1a cells by improving the immunosuppressive microenvironment. The in vivo and in vitro mechanistic studies revealed that CUR combined with ATO primarily upregulated the expression of LC3 protein to promote the formation of autophagosomes in AML cells, downregulated the expression of the hypoxia-inducible factor HIF-1α protein to ameliorate the immunosuppressive microenvironment of AML, and..."

IO biomarker • Journal • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • BCL2 • BECN1 • CASP3 • CD34 • GZMB • HIF1A • IL10 • MICA • NKG2D • ULBP1

Anthracycline and arsenic trioxide-based regimens for the treatment of acute promyelocytic leukemia: thiamine levels monitoring importance. (PubMed, Curr Res Transl Med) - No abstract available

Journal • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

CRISPR/Cas9-Based Modeling of JAK2 V617F Mutation in K562 Cells Reveals Enhanced Proliferation and Sensitivity to Therapeutic Agents. (PubMed, Int J Mol Sci) - "Interferon α2a (IFN-α2a) and arsenic trioxide were also administered to the cells to explore their potential effects...Moreover, the modified cells were able to differentiate into megakaryocyte-like cells following stimulation with phorbol 12 myristate 13 acetate (PMA). Taken together, the results of the present study have shown that the CRISPR/Cas9-modified JAK2 V617F model may be used as a disease model in the search of novel therapies for MPNs."

Journal • Essential Thrombocythemia • Hematological Disorders • Myelofibrosis • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera • Thrombocytosis • ABL1 • IFNA1 • JAK2

Uncovering dendritic cell specific biomarkers for diagnosis and prognosis of cardiomyopathy using single cell RNA sequencing and comprehensive bioinformatics analysis. (PubMed, Sci Rep) - "Prospective chemical substances such as tretinoin, valproic acid, and arsenic trioxide have been predicted to be linked to cardiomyopathy treatment...This study identifies molecular indicators at the RNA and protein levels that may be useful in improving understanding of molecular causes, early diagnosis, and devising favorable cardiomyopathy treatment. More research will be needed to validate our predicted findings as future clinical biomarkers."

Biomarker • Journal • Cardiomyopathy • Cardiovascular • Infectious Disease • Transplant Rejection • FOXC1 • GATA2 • HLA-B • IRF1 • IRF7 • ITGAX • MIR129 • MIR129-2 • MIR26A1 • MX1 • STAT3

Protective Effects of Ellagic Acid Against Arsenic-Induced Hepatotoxicity in Male Wistar Rats: Impact of Heme Oxygenase-1 Upregulation. (PubMed, Food Sci Nutr) - "In contrast, Group IV demonstrated reduced liver damage, mild VEGF expression, HO-1 upregulation, and improvements in biochemical markers. Overall, the findings suggest that EA alleviated AsIII-induced hepatotoxicity via the HO-1 upregulation pathway, highlighting the therapeutic potential of EA in managing liver toxicity."

Journal • Preclinical • HMOX1

Arsenic trioxide inhibits refractory lymphoma by targeting BCL6 and triggering degradation (SID 2025) - "In addition, the effectiveness of ATO for the treatment of lymphoma in vivo has proved through animal models. This work reveals the mode of action of the ATO in molecular level and its specificity for refractory lymphoma, and is expected to be a potential therapeutical strategy for refractory lymphoma and IVLBCL with a typical skin phenotype."

B Cell Lymphoma • Hematological Malignancies • Lymphoma • Oncology • Targeted Protein Degradation • BCL6

As Many Diseases as They Please: A Case of Respiratory Failure Due to Overlap of Differentiation Syndrome and Staphylococcal Pneumonia (ATS 2025) - "This abstract is funded by: None Introduction: Differentiation syndrome (DS) is a life-threatening complication of acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA) and/or arsenic trioxide (ATO)...She had been on prophylactic prednisone for DS which was switched to dexamethasone, and chemotherapy was held...She received vancomycin and cefepime, and was transferred to the ICU...However, the presence of another condition, such as a pneumonia, does not rule out a diagnosis of DS. All patients in the right setting (known malignancy and medication associated with DS) should receive empiric treatment with steroids."

Clinical • Acute Promyelocytic Leukemia • Cardiovascular • Congestive Heart Failure • Heart Failure • Hematological Malignancies • Infectious Disease • Leukemia • Oncology • Pneumonia • Respiratory Diseases

Long-term Survival of a Lung Transplant Recipient With Acute Promyelocytic Leukemia and Anatomical Variance in the Donor (ATS 2025) - "The patient's immunosuppressive regimen included prednisone, tacrolimus, and mycophenolate mofetil (MMF)...Induction therapy with arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) reduced blast count to 0.4% by day 30...This case highlights a unique instance of long-term survival in a lung transplant recipient with APL who was successfully treated with ATO and ATRA as evidenced by achieving undetectable blast levels. Early and aggressive treatment, along with individualized management, proved essential. Prompt recognition of anatomical variation in the donor's lung and a stepwise approach—such as listing for a re-redo lung transplant when needed—is critical for proactively improving outcomes by addressing potential complications."

Clinical • Acute Promyelocytic Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Leukopenia • Oncology • Otorhinolaryngology • Respiratory Diseases • Transplantation • RARA

Tragic Transformations and Differentiation Syndrome (ATS 2025) - "This abstract is funded by: None Introduction: Differentiation syndrome (DS) is a life-threatening adverse drug reaction caused by differentiating agents, including all-trans retinoic acid, arsenic trioxide, inhibitors of mutant isocitrate dehydrogenase (e.g., enasidenib), and the FLT3 inhibitor gilteritinib...Case: An 80-year-old female with a history of polycythemia vera and newly diagnosed AML, on decitabine, venetoclax, and enasidenib...Enasidenib was discontinued due to suspected DS, and she was treated with dexamethasone for five days...Despite initial oxygenation improvement with prone positioning, she remained hypotensive requiring norepinephrine, vasopressin, angiotensin II, and hydrocortisone...Leukocytosis worsened, and decitabine and hydroxyurea were initiated due to concern for uncontrolled acute leukemia...Prompt initiation of systemic glucocorticoids is critical in the management of DS, and this condition should be considered in patients receiving active..."

Cardiovascular • Febrile Neutropenia • Hematological Malignancies • Hepatology • Leukemia • Liver Failure • Myocardial Ischemia • Oncology • Polycythemia Vera • Renal Disease • Respiratory Diseases • FLT3

Role of high-dose vitamin C as adjunct treatment in gastric and colorectal cancers: A systematic review. (ASCO 2025) - "Most patients received ascorbic acid with FOLFOX (97.7%), FOLFIRI (0.38%), or arsenic trioxide (1.9%)...established the RP2D of ascorbic acid at 1.5 g/kg/day (D1–3) with mFOLFOX6 or FOLFIRI...A phase III VITALITY trial randomized 442 untreated metastatic CRC patients to FOLFOX ± bevacizumab with (n = 221) or without (n = 221) 1.5 g/kg/day of ascorbic acid (D1–3)... High-dose ascorbic acid has demonstrated potential in inhibiting cancer cell growth in gastrointestinal malignancies, particularly colorectal cancer and gastric cancer. However, clinical trials have shown limited therapeutic benefits, highlighting the need for further research to clarify its role in cancer treatment."

Review • Colorectal Cancer • Fatigue • Gastric Cancer • Oncology • Pain • Solid Tumor

Identification and validation of arsenic-associated genes and risk model for predicting lung cancer. (ASCO 2025) - "Arsenic trioxide, a carcinogen in tobacco smoke, is linked to DNA damage and tumorigenesis, increasing lung cancer risk in exposed individuals, including smokers... This study identifies four robust biomarkers among 88 significant genes for lung cancer risk prediction, achieving high model accuracy. These findings highlight the utility of arsenic-associated genes in assessing cancer risk and advancing understanding of heavy metal toxicity in lung cancer. Further investigation of these biomarkers could provide insights into their molecular roles and enhance predictive and therapeutic strategies."

Bladder Cancer • Genito-urinary Cancer • Lung Cancer • Oncology • Solid Tumor • ADARB1

Venetoclax as cytoreductive therapy in high-risk acute promyelocytic leukemia: A potential alternative to anthracyclines. (ASCO 2025) - "All patients received standard ATRA (All-Trans Retinoic Acid) + ATO (Arsenic Trioxide) induction. This study demonstrates the feasibility of using venetoclax for cytoreduction in high-risk APL patients. Venetoclax effectively reduced tumor burden while minimizing the risks associated with anthracyclines. These encouraging results warrant further investigation into the potential role of venetoclax in high-risk APL to improve patient outcomes and mitigate treatment-related toxicities."

Acute Promyelocytic Leukemia • Coronary Artery Disease • Heart Failure • Hematological Disorders • Hematological Malignancies • Leukemia • Mucositis • Neutropenia • Oncology

Silencing NRF2 enhances arsenic trioxide-induced ferroptosis in hepatocellular carcinoma cells. (PubMed, PLoS One) - "ATO significantly promoted ferroptosis in HCC cells, and NRF2 knockdown enhanced the cytotoxic effects of ATO."

Journal • Acute Promyelocytic Leukemia • Hematological Malignancies • Hepatocellular Cancer • Leukemia • Oncology • Solid Tumor • GPX4 • SLC7A11

Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma (clinicaltrials.gov) - P2 | N=80 | Active, not recruiting | Sponsor: Yang Li | Recruiting ➔ Active, not recruiting

Enrollment closed • Neuroblastoma • Oncology • Solid Tumor

Arsenic-induced neurocardiac toxicity and protective role of Resveratrol: histopathological and molecular insights. (PubMed, J Mol Histol) - "Adult mice were segregated into control and experimental groups; controls received distilled water, while experimental groups received oral gavage of arsenic trioxide (ATO) at low (2 mg/kg bw) or high (4 mg/kg bw) doses for 45 days...We also examined the expression of ER-α in the preoptic area of the hypothalamus and indicated downregulation of ER-α due to prolonged ATO exposure. Our findings highlight Resveratrol as a potent neurocardiac protector against ATO toxicity via estrogen signaling modulation, supporting its therapeutic potential in arsenic poisoning."

Journal • Cardiovascular • Fibrosis • Immunology • ER

Advantage of Tolerability following Arsenic Trioxide-VTD vs VRD in newly diagnosed multiple myeloma patients: a prospective, open-label study. (PubMed, Int J Med Sci) - "The standard front-line VRD regimen (bortezomib/lenalidomide/dexamethasone) achieves high efficacy but is associated with significant toxicity, leading to infections, bone marrow suppression, and treatment discontinuation in approximately 20% of patients...Prior studies suggest adding arsenic trioxide to bortezomib/dexamethasone (BD) enhances remission depth with acceptable safety, while bortezomib/thalidomide/dexamethasone (VTD) offers reduced toxicity, but lower efficacy compared to VRD...Additionally, AVTD was associated with lower treatment costs. In conclusion, the AVTD regimen offers a safer, more cost-effective alternative to VRD for NDMM, particularly in older adult patients, without compromising treatment efficacy."

Clinical • Journal • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Oncology

Venetoclax combined with ATRA shows promising therapeutic potential for TFG:: RARA variant APL: a case report. (PubMed, Front Oncol) - "Most cases of acute promyelocytic leukemia (APL) are driven by the PML::RARA fusion gene, which is sensitive to differentiation induction therapy comprising of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Currently, the overall survival (OS) of the patient has exceeded 30 months, and the progression-free survival (PFS) has reached 29 months. Our results suggest that venetoclax combined with ATRA may be an ideal treatment option for patients with TFG::RARA variant APL."

Journal • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

THE EFFICIENCY AND SAFETY OF LOW-DOSE VENETOCLAX AS A PROPHYLAXIS FOR DIFFERENTIATION SYNDROME IN THE INDUCTION REGIMEN OF ACUTE PROMYELOCYTIC LEUKEMIA (EHA 2025) - "Background: Owing to the induction regimen of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO), acute promyelocytic leukemia (APL) has become the only type of acute myeloid leukemia (AML) that can be cured without haploidentical hematopoietic stem cell transplantation (haplo-HSCT)... Our study underlined the effective low-dose venetoclax as a prophylaxis of DS during the induction therapy of ATRA and ATO, reducing the early death. No death was observed and the requirement of blood products also get alleviate. Randomized controlled trials with more enrolled patients are needed to be conducted to demonstrate tthe efficiency and safety in future."

Clinical • Acute Kidney Injury • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Hematological Disorders • Hepatology • Infectious Disease • Leukemia • Lymphoma • Nephrology • Oncology • Pneumonia • Pulmonary Disease • Renal Disease • Respiratory Diseases • BCL2

DO APL PATIENTS TREATED WITH ATO+ATRA ACHIEVE A NORMAL LIFE EXPECTANCY? INSIGHTS FROM THE LONG TERM FOLLOW-UP OF THE GIMEMA APL0406 STUDY (EHA 2025) - "Background: Acute Promyelocytic Leukemia (APL) has undergone a paradigm shift in treatment with the introduction of arsenic trioxide (ATO) and all-trans retinoic acid (ATRA), leading to high remission and survival rates. These findings suggest that APL patients achieving remission with ATO+ATRA may experience long-term survival comparable to that of the general population. Given that this is the first study to explore this question, further research with larger cohorts and extended follow-up is warranted to confirm these observations and refine mortality risk estimates."

Clinical • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

VENETOCLAX INDUCES MITOCHONDRIAL APOPTOSIS AND AUTOPHAGY TO OVERCOME ARSENIC TRIOXIDE RESISTANCE IN ACUTE PROMYELOCYTIC LEUKEMIA (EHA 2025) - "Taken together, these findings suggest that venetoclax overcomes ATO resistance by reducing mitochondrial respiration and promoting autophagy."

IO biomarker • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • BCL2 • BECN1 • LAMP1 • PML

Long-term Persistence of Dysplastic Features in Patients with Acute Promyelocytic Leukemia Treated with All-trans Retinoic Acid and Arsenic Trioxide. (PubMed, Mediterr J Hematol Infect Dis) - No abstract available

Journal • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

ROBUST MOUSE MODEL OF SECONDARY ACUTE MYELOID LEUKEMIA: REVEALING KEY ROLE OF TP53 MUTATIONS AND PERSISTENT STAT5 ACTIVATION. (EHA 2025) - "Pharmacological reactivation of mutant p53 (V272M) using Arsenic Trioxide (ATO) restored wild-type function, leading to the suppression of leukemic transformation... This treatment model opens the possibility to test on single cells, the changes in chromatin and gene expression during inhibition of blast proliferation and survival. Collectively, our study highlights the critical role of TP53 mutations in sAML pathogenesis and demonstrates the therapeutic potential of targeting both mutant p53 and STAT5 signaling to mitigate disease progression in hematological malignancies."

Preclinical • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Leukemia • Myeloproliferative Neoplasm • Oncology • JAK2 • STAT5 • STAT5AWqe • TP53

THE RESULTS OF TREATMENT OF ACUTE LEUKEMIA DIAGNOSED DURING PREGNANCY (EHA 2025) - "The efficiency and toxicity of induction therapy during pregnancy or in the early postpartum period in all variants of acute leukemia are comparable with those in non-pregnant women. Pregnancy at the debut of AML is an unfavorable risk factor, which can be eliminated by performing allo-HSCT in CR1. The adverse prognosis factors were more frequent in pregnant ALL patients, but this factors did not have a reliable effect on survival rates."

Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • KMT2A

TARGETING METABOLIC ALTERATIONS IN PML::RARα+ MYELOID CELLS TO OVERCOME RESISTANCE AND RELAPSE IN ACUTE PROMYELOCYTIC LEUKEMIA. (EHA 2025) - "Although therapies based on all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) have made APL one of the most curable AML subtypes, approximately 1% of cases are resistant, and 5% relapse...This metabolic dependency increased sensitivity to the combination of VTX-269 and azacitidine (VTX-AZA), suggesting a potential targeted therapy for resistant or relapsed APL. Our findings highlight the importance of metabolic reprogramming in APL, emphasizing the role of fatty acid metabolism and OXPHOS in disease pathophysiology. These results provide insights into novel therapeutic strategies that exploit APL's metabolic vulnerabilities, offering promising avenues for improved treatment outcomes in resistant and relapsed cases."

Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CD34 • CD36 • RARA • SCARB1

OUTCOME FOR PEDIATRIC PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA IN RUSSIA AND BELARUS TREATED ON THE APL 2003/2008 PROTO?OLS (EHA 2025) - "This protocols were based on the use of combination of ATRA in the dose of 25mg/m2 and anthracycline/ Ara-C based chemotherapy in induction and 2 blocks of consolidation and 1,5 years maintenance with 6-MP, MTX and ATRA. The decreasing of early death rates is key to improving APL treatment results in children in Russia and Belarus. The new APL protocol base on the use of ATRA and Arsenic trioxide ± Anthracyclines will start in 2025."

Clinical • Acute Promyelocytic Leukemia • Cerebral Hemorrhage • Hematological Disorders • Hematological Malignancies • Leukemia • Oncology • Pediatrics